How to Get Tresiba (Insulin Degludec) in Indiana

What Is Tresiba and Why Doctors Prescribe It

Tresiba is a brand-name basal insulin with a duration of action that exceeds 42 hours, longer than any other approved insulin on the U.S. market. It covers background glucose needs between meals and overnight without the pronounced peak seen with insulin glargine U-100 or insulin detemir. The DEVOTE trial (N=7,637) showed degludec produced significantly fewer severe hypoglycemic episodes than glargine U-100 in high-cardiovascular-risk type 2 diabetes patients, with a rate ratio of 0.60 (95% CI 0.48 to 0.76, P<0.001) [1]. That hypoglycemia advantage is often the clinical reason an Indiana provider switches a patient from a first-generation basal insulin to Tresiba.

The FDA approved insulin degludec in September 2015 under NDA 203313 for both type 1 and type 2 diabetes in adults, and later for pediatric patients aged 1 year and older [2]. Approved doses range from U-100 (FlexTouch pen, 100 units/mL) to U-200 (FlexTouch pen, 200 units/mL). Starting doses for insulin-naive type 2 patients typically begin at 10 units once daily, titrated by 2 units every 3 days based on fasting glucose targets outlined in the American Diabetes Association Standards of Care [3].

Degludec's flat, peakless pharmacokinetic profile is attributable to its mechanism: the drug forms soluble multi-hexamers at the injection site that slowly dissociate into monomers before absorption [4]. That mechanism makes day-to-day glycemic variability measurably lower than with glargine. The BEGIN Basal-Bolus Type 1 trial (N=629) confirmed non-inferiority versus glargine on HbA1c reduction while showing a 25% lower rate of nocturnal hypoglycemia [5].

Indiana's Legal Framework for Tresiba Prescriptions

Any licensed prescriber in Indiana may write a Tresiba prescription, provided the patient encounter meets Indiana's standard-of-care requirements. Indiana Code Title 25 governs prescribing authority for MDs, DOs, NPs, and PAs [6]. Since July 2023, Indiana advanced practice registered nurses (APRNs) with full practice authority no longer require a collaborative agreement to prescribe Schedule II through V controlled substances or, by extension, non-controlled prescription medications like insulin. This change expanded same-day telehealth prescribing access considerably for patients in rural Indiana counties such as Crawford, Orange, and Martin.

Physician assistants in Indiana still operate under a supervising physician agreement, but that agreement does not prohibit PA-initiated insulin therapy. A PA working in a primary care or endocrinology practice can evaluate, diagnose, and prescribe Tresiba independently within that supervisory structure.

Telehealth encounters satisfy the prescribing standard in Indiana as long as a valid prescriber-patient relationship is established. Indiana does not require an in-person visit before a telehealth provider prescribes a non-controlled medication like insulin degludec [7]. Platforms operating under Indiana law can conduct a synchronous video consultation, review uploaded records including a recent HbA1c and fasting glucose log, and transmit an electronic prescription to any Indiana-licensed pharmacy on the same day.

How to Get a Tresiba Prescription Step by Step

Getting Tresiba in Indiana follows a straightforward clinical pathway once you understand the documentation your provider needs.

Step 1. Gather your records. Collect your most recent HbA1c (within 90 days is ideal), a 7-to-14-day fasting glucose log, your current insulin regimen and doses, any history of severe hypoglycemia, and your insurance card. If you have a continuous glucose monitor (CGM) report, export the last 14 days of data as a PDF.

Step 2. Choose a prescriber. Options include your existing primary care provider, an endocrinologist (Indiana University Health, Eskenazi Health, Franciscan Health, and Beacon Health System all maintain endocrinology panels), or a telehealth platform licensed in Indiana. Telehealth typically offers appointments within 24 to 72 hours versus 3 to 8 weeks for in-person endocrinology.

Step 3. Complete the clinical evaluation. The provider will review your fasting glucose variability, hypoglycemia risk, renal function (eGFR affects titration thresholds), and current basal-to-bolus ratio if applicable. The ADA recommends an HbA1c target of <7.0% for most non-pregnant adults with type 2 diabetes, and <7.5% for adults with type 1 diabetes who have significant hypoglycemia unawareness [3].

Step 4. Receive and fill the prescription. Electronic prescriptions route directly to your pharmacy. Major Indiana chains (Walgreens, CVS, Kroger Health, Meijer Pharmacy) stock both Tresiba U-100 and U-200. Independent pharmacies may require 24 to 48 hours to order if not in stock.

Step 5. Complete prior authorization if required. Most commercial plans and the Indiana Medicaid managed care organizations (MCOs) require PA before dispensing Tresiba. Your prescriber submits clinical documentation. Approval typically arrives in 3 to 10 business days for commercial plans and 5 to 15 business days for Medicaid MCOs.

Labs Required Before and During Tresiba Therapy

No single lab panel is mandatory before starting insulin degludec, but evidence-based guidelines support a standard baseline assessment to optimize safety and titration. The ADA Standards of Medical Care in Diabetes recommends the following at initiation [3]:

• HbA1c, establishes baseline glycemic control; target generally <7.0% for most adults.
• Fasting plasma glucose, used to set the initial starting dose and titration schedule.
• Basic metabolic panel (BMP), includes serum creatinine and eGFR. No dose adjustment is required for renal impairment per the FDA label, but eGFR guides overall diabetes management intensity [2].
• Thyroid-stimulating hormone (TSH), recommended in patients with type 1 diabetes given the elevated co-prevalence of autoimmune thyroid disease, approximately 17 to 30% [8].
• Lipid panel, routine cardiovascular risk assessment per ADA and ACC/AHA guidelines [9].
• Urine albumin-to-creatinine ratio (UACR), screens for diabetic kidney disease, which modifies hypoglycemia risk.

Follow-up labs at 3 months post-initiation should include a repeat HbA1c. The DEVOTE trial used HbA1c as its primary glycemic endpoint and demonstrated that degludec-treated patients achieved a mean HbA1c of 7.5% versus 7.6% with glargine at 2 years (non-inferiority margin 0.4%, met), while the hypoglycemia advantage was statistically significant [1].

The HealthRX clinical team uses a structured pre-Tresiba checklist: HbA1c, fasting glucose log (minimum 7 days), BMP, UACR, TSH (type 1 only), lipid panel, and a hypoglycemia risk stratification score based on age over 65, eGFR <45, and history of severe hypoglycemia in the past 12 months. Patients scoring 2 or more on that three-point scale start at a 20% lower initial dose with more frequent titration check-ins.

Telehealth Providers Prescribing Tresiba in Indiana

Indiana explicitly permits telehealth prescribing of non-controlled substances. The Indiana Telehealth Act (IC 25-1-9.5) defines a valid provider-patient relationship through synchronous audio-video communication and allows electronic transmission of prescriptions without a prior in-person visit [7]. This opens Tresiba access to patients in every Indiana county, including those without a local endocrinologist.

Telehealth platforms that hold Indiana prescriber licenses and operate in the diabetes/hormone-therapy space include specialty telehealth providers, direct primary care (DPC) practices, and integrated telehealth groups affiliated with large Indiana health systems. When evaluating any platform, confirm that the prescribing clinician holds an active Indiana license (verify at the Indiana Professional Licensing Agency, pla.in.gov), that the platform transmits to a DEA-registered pharmacy, and that it can submit prior authorization documentation on your behalf.

A typical Indiana telehealth Tresiba visit runs 20 to 30 minutes for new patients. The provider reviews uploaded labs, current medications, and your glucose data, then transmits the prescription electronically. Most platforms process same-day prescriptions before 3 p.m. local time. Delivery timelines depend on whether you use local pharmacy pickup (same day to next day) or mail-order pharmacy (3 to 7 business days) [10].

Indiana Medicaid and Insurance Coverage for Tresiba

Indiana Medicaid (administered through MCOs including Anthem, MDwise/Wellcare, Molina, and UnitedHealthcare) covers Tresiba for type 1 diabetes. Coverage for type 2 diabetes under Indiana Medicaid is not guaranteed and requires prior authorization with documentation that first-line basal insulins (glargine or detemir) have failed or caused intolerable hypoglycemia [11].

Commercial plans in Indiana vary. Formulary placement for Tresiba ranges from Tier 2 (preferred brand) to Tier 3 (non-preferred brand) depending on the plan year and MCO. The ADA's 2024 Standards of Care state that "insulin degludec may be preferred over insulin glargine U-100 in patients with recurrent nocturnal hypoglycemia or significant glycemic variability" [3], and this language is increasingly used in PA letters to support Tresiba over first-generation basals.

What prior authorization documentation typically requires:

1. Diagnosis code (E10.x for type 1, E11.x for type 2) with current HbA1c.
2. Trial and failure of at least one preferred basal insulin (usually glargine U-100 or biosimilar glargine), defined as inadequate glycemic control or documented hypoglycemia.
3. Prescriber attestation of clinical necessity referencing DEVOTE outcomes data or ADA guideline language.
4. Current medication list and dose.

The Indiana Medicaid preferred drug list (PDL) is updated quarterly by the Indiana Family and Social Services Administration (FSSA) [11]. Patients whose plans deny Tresiba on first submission have a right to appeal; the Indiana External Review process under IC 27-13-36 allows independent medical review within 45 days of denial.

Tresiba Pharmacy Access in Indiana

Every major retail pharmacy chain operating in Indiana stocks insulin degludec in both U-100 and U-200 formulations. Walgreens, CVS, Kroger Pharmacy, Meijer Pharmacy, and Walmart Pharmacy are the five largest by location count. Independent pharmacies and compounding pharmacies designated as 503A facilities under the Drug Quality and Security Act are also licensed to handle insulin degludec [12].

503A compounding pharmacies in Indiana can prepare customized insulin degludec formulations, for example adjusted concentrations or combination pens, when a licensed prescriber writes a prescription for an individual patient with a documented clinical need that the commercially available product cannot meet. The Indiana Board of Pharmacy licenses 503A facilities, and patients can verify a pharmacy's standing at the Indiana Professional Licensing Agency portal. The FDA maintains oversight of compounding quality standards under 21 CFR Part 211 [12].

Cash-pay pricing for Tresiba at Indiana retail pharmacies without insurance runs approximately $350 to $450 for a box of five FlexTouch pens (300 units each, U-100) as of 2025. GoodRx and similar discount programs may reduce that to $270 to $310 at select locations. The Novo Nordisk My$99Insulin program caps the monthly cost at $99 for eligible uninsured or underinsured patients regardless of the quantity prescribed [13].

Mail-order pharmacies licensed to ship to Indiana addresses are an alternative for patients in rural areas. Indiana law permits out-of-state mail-order pharmacies to fill prescriptions provided they hold an Indiana nonresident pharmacy permit issued by the Indiana Board of Pharmacy.

Transferring a Tresiba Prescription to Indiana

Patients relocating to Indiana from another state can transfer their Tresiba prescription under federal and Indiana pharmacy law. Federal law (21 USC 353) permits the one-time transfer of a prescription for a non-controlled substance between pharmacies. The receiving Indiana pharmacy contacts the original pharmacy directly to confirm the prescription's validity and remaining refills.

For patients who established care with a telehealth provider in another state, the prescribing relationship may not automatically extend to Indiana. Telehealth prescribers must hold an active Indiana license to legally prescribe to Indiana residents. If your out-of-state telehealth provider is not licensed in Indiana, request a 30-day emergency supply from your current pharmacy while establishing care with an Indiana-licensed provider. The Indiana Medical Licensing Board grants temporary permits in some circumstances; providers can apply at pla.in.gov.

Patients transferring insulin prescriptions should also confirm that the new Indiana pharmacy carries the same device (FlexTouch pen vs. vial), since the U-200 formulation is not universally stocked at every location.

Dosing, Titration, and Safety Considerations

Tresiba is dosed once daily at any time of day, with flexibility of up to 8 hours between injections without a clinically significant loss of effect. This schedule flexibility, confirmed in the FLEX trial, distinguishes degludec from other basal insulins that require stricter timing [14]. The FLEX trial demonstrated no significant difference in HbA1c or hypoglycemia rates when injections were given at varying times versus fixed times.

The standard starting dose for insulin-naive type 2 diabetes patients is 10 units subcutaneously once daily. Titration follows a simple algorithm: increase by 2 units every 3 days if fasting glucose exceeds 90 mg/dL consistently. The FDA label recommends targeting a fasting plasma glucose of 80 to 90 mg/dL for most patients [2]. For type 1 diabetes, Tresiba replaces the existing basal insulin unit for unit as the starting conversion.

The most common adverse event is hypoglycemia. In DEVOTE, the rate of severe hypoglycemia with degludec was 0.92 episodes per patient-year versus 1.52 with glargine U-100 (rate ratio 0.60, P<0.001) [1]. Patients over age 65, those with eGFR <30, and those with hypoglycemia unawareness require closer monitoring during the titration phase. The Endocrine Society guideline on diabetes management in older adults recommends a less aggressive HbA1c target of 7.5 to 8.0% and cautions against tight fasting glucose targets in this group [15].

Injection site reactions occur in fewer than 2% of patients in clinical trials [2]. Rotating injection sites across the abdomen, thigh, and upper arm reduces the risk of lipohypertrophy, which can reduce insulin absorption by up to 25% [16].

What to Expect After Starting Tresiba in Indiana

Most patients notice improved fasting glucose stability within 3 to 5 days of the first injection, as steady-state plasma concentrations of insulin degludec are reached after approximately 2 to 3 days of once-daily dosing [2]. Full titration to target typically takes 2 to 6 weeks depending on baseline HbA1c and insulin sensitivity.

Your Indiana prescriber should schedule a follow-up visit or telehealth check-in at 4 weeks post-initiation to review glucose logs, assess for hypoglycemia, and adjust the dose. A formal HbA1c recheck at 3 months confirms whether the titrated dose is achieving the glycemic target established at the initial visit.

CGM use alongside Tresiba is supported by the ADA and associated with better outcomes. The MOBILE trial (N=175) showed that CGM combined with basal insulin therapy reduced HbA1c by an additional 0.4 percentage points compared to fingerstick monitoring alone in adults with type 2 diabetes not on rapid-acting insulin [17]. Indiana Medicaid covers CGM for patients with type 1 diabetes; coverage for type 2 patients on basal insulin varies by MCO.

Patients who experience persistent fasting hyperglycemia above 130 mg/dL despite adequate Tresiba titration may require addition of a GLP-1 receptor agonist or mealtime insulin. The ADA recommends GLP-1 agonist addition before mealtime insulin in most type 2 diabetes patients with residual hyperglycemia, given superior weight outcomes and lower hypoglycemia risk [3].